Correlation of serum MAp44 protein concentration with degree of myocardial injury and 30-day prognosis in patients with acute myocardial infarction.

OBJECTIVE

To analyze the relationship between serum mannan-binding lectin-associated protein 44 (MAp44) level and myocardial injury severity in acute myocardial infarction (AMI) patients, and explore its value for 30-day prognostic assessment.

METHODS

A retrospective study included 128 AMI patients admitted to The First Hospital of Zhangjiakou from January 2023 to June 2024, divided into mild (n=57) and severe myocardial injury groups (n=71). General data and MAp44 levels were compared. For 30-day prognosis, patients were stratified into a major adverse cardiovascular event (MACE, n=37) and a non-MACE group (n=91). Univariate and multivariate analyses identified poor prognostic factors, and predictive values of indicators were compared. An independent cohort (82 AMI patients, February-October 2025) validated the model.

RESULTS

The severe group had significantly lower MAp44 and higher cardiac troponin T (cTnT) than the mild group (P<0.001). MAp44 was negatively correlated with cTnT (r=-0.666, P<0.001). The 30-day MACE incidence was 28.91%. Extensive infarction, ≥2 coronary lesions, elevated cTnT, and low MAp44 were MACE risk factors (P<0.05). The combined model (infarction size + coronary lesions + cTnT, and + MAp44) had the highest prognostic value (AUC=0.890, sensitivity =78.40%, specificity =83.50%), with 84.1% accuracy in the validation cohort.

CONCLUSION

Serum MAp44 levels decrease with increasing myocardial injury severity in AMI patients; low MAp44 is an independent risk factor for 30-day MACE.